ArticleBMC infectious diseases2025
Clinical features of pyogenic vertebral osteomyelitis and factors associated with adverse clinical outcome: a retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPyogenic vertebral osteomyelitis (PVO) is an increasingly prevalent disease that poses significant challenges in clinical management. The present study aimed to evaluate the clinical characteristics of PVO and identify the risk factors associated with adverse outcomes.
methodsAdult patients diagnosed with PVO at a tertiary education and research hospital in Turkiye between January 2015 and January 2019 were included in this retrospective study. Adverse outcome was defined as the persistence or progression of PVO-related symptoms and signs at the end of treatment.
resultsOf the 68 PVO patients included in the study, 41% had a history of vertebral surgery, and 22% had a central venous catheter. Neurological deficit was observed in 47% of the patients. The most commonly isolated pathogen was Staphylococcus aureus (27%). The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 33–54), and 46% of patients underwent surgical interventions. Adverse outcome was observed in 28% of patients. In multivariate analysis, S. aureus infection, motor weakness, and the presence of a sinus tract were demonstrated as the independent risk factors for adverse outcome. Furthermore, the C-reactive protein (CRP) values at admission and on the 7th day of antimicrobial therapy were shown to be predictive of adverse outcome (≥ 54.5 mg/L and ≥ 38 mg/L, respectively).
conclusionIndependent predictors of adverse outcome in patients with PVO were S. aureus infection, motor weakness, and the presence of a sinus tract. Furthermore, CRP measurement at presentation and on day 7 of antimicrobial therapy was found to contribute to the prediction of adverse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.